Literature DB >> 2688654

Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine.

V Heinemann1, W Plunkett.   

Abstract

Tetrahydrodeoxyuridine (dTHU) inhibits deoxycytidine deaminase and, after intracellular phosphorylation to the active 5'-monophosphate, also inhibits deoxycytidylate deaminase (dCMPD). Because in vitro studies have shown that dCMPD may regulate pyrimidine deoxynucleotide metabolism, the objective of this study was to investigate the effects of dTHU on deoxynucleotide metabolism in whole cells. Nearly complete inhibition of dCMPD, measured in intact CCRF-CEM cells by incorporation of [14C]dCyd into dTTP, occurred after a 45-min incubation with 100 microM dTHU. This was accompanied by an 8-fold dCTP pool expansion, although dATP, dTTP, dGTP, and ribonucleoside triphosphate pools were unaffected. Tetrahydrouridine, which inhibits deoxycytidine deaminase exclusively, had no effect on nucleotide pools. The dCTP pool expansion was directly proportional to the dTHU concentration (3-100 microM) and reached a maximum after 2 hr. Inhibition of ribonucleotide reductase by hydroxyurea completely prevented the dTHU-induced dCTP pool expansion, indicating that the substrate of dCMPD was derived from the ribonucleotide pool and that CDP was the predominant precursor of dCTP. dTHU-mediated inhibition of dCMPD appeared reversible. Exposure of cells to 100 microM dTHU followed by washing into fresh medium resulted in a linear decrease of the dCTP pool and an increase in the dTTP pool. The increased dCTP concentration after preincubation with dTHU was associated with an inhibition of deoxycytidine kinase, as indicated by a reduced capacity of cells to phosphorylate ara-C. dTHU is a useful new tool for investigating the role of dCMPD in the regulation of deoxynucleotide metabolism in whole cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688654     DOI: 10.1016/0006-2952(89)90693-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.

Authors:  Md Faiz Ahmad; Intekhab Alam; Sarah E Huff; John Pink; Sheryl A Flanagan; Donna Shewach; Tessianna A Misko; Nancy L Oleinick; William E Harte; Rajesh Viswanathan; Michael E Harris; Chris Godfrey Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

2.  Chloroviruses encode a bifunctional dCMP-dCTP deaminase that produces two key intermediates in dTTP formation.

Authors:  Yuanzheng Zhang; Frank Maley; Gladys F Maley; Garry Duncan; David D Dunigan; James L Van Etten
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

3.  Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.

Authors:  Sarah E Huff; Faiz Ahmad Mohammed; Mu Yang; Prashansa Agrawal; John Pink; Michael E Harris; Chris G Dealwis; Rajesh Viswanathan
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

Review 4.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

5.  Synthesis of deoxytetrahydrouridine.

Authors:  Jolanna Norton; Hiroshi Matsuo; Shana J Sturla
Journal:  J Org Chem       Date:  2009-03-06       Impact factor: 4.354

6.  Structure-guided design of anti-cancer ribonucleotide reductase inhibitors.

Authors:  Tessianna A Misko; Yi-Ting Liu; Michael E Harris; Nancy L Oleinick; John Pink; Hsueh-Yun Lee; Chris G Dealwis
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

7.  Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency.

Authors:  Caterina Garone; Beatriz Garcia-Diaz; Valentina Emmanuele; Luis C Lopez; Saba Tadesse; Hasan O Akman; Kurenai Tanji; Catarina M Quinzii; Michio Hirano
Journal:  EMBO Mol Med       Date:  2014-08       Impact factor: 12.137

8.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Authors:  Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah
Journal:  PLoS Med       Date:  2017-09-07       Impact factor: 11.069

9.  SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

Authors:  Nikolas Herold; Sean G Rudd; Kumar Sanjiv; Juliane Kutzner; Julia Bladh; Cynthia B J Paulin; Thomas Helleday; Jan-Inge Henter; Torsten Schaller
Journal:  Cell Cycle       Date:  2017-04-24       Impact factor: 4.534

Review 10.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.